Overview

Long-Term Safety Study of Canagliflozin (TA-7284) in Combination With GLP-1 Analogue in Patients With Type 2 Diabetes Mellitus

Status:
Completed

Trial end date:
2016-03-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to evaluate the safety and efficacy of Canagliflozin (TA-7284) in combination with GLP-1 analogue in patients with type 2 Diabetes for 52 weeks.

Phase:

Phase 4

Details

Lead Sponsor:

Mitsubishi Tanabe Pharma Corporation

Treatments:

Canagliflozin
Glucagon
Glucagon-Like Peptide 1